Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mina Pastagia, MD, MS
Armata Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Children'S Hospital Los Angeles
Los Angeles, California, United States
- University of South Florida
Tampa, Florida, United States
- St. Luke'S Cystic Fibrosis Center of Idaho
Boise, Idaho, United States
- Northwestern University
Chicago, Illinois, United States
- University of Iowa
Iowa City, Iowa, United States
- the University of Kansas Medical Center
Kansas City, Kansas, United States
- Johns Hopkins University
Baltimore, Maryland, United States
- Boston Children'S Hospital
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Harper University Hospital
Detroit, Michigan, United States
- Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
- New York Medical College
Valhalla, New York, United States
- University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
- Nationwide Children'S Hospital
Columbus, Ohio, United States
- the Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
- Medical University of South Carolina
Charleston, South Carolina, United States
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
- University of Texas Southwestern
Dallas, Texas, United States
- University of Washington
Seattle, Washington, United States
- University of Wisconsin
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Dec 2020
- Primary completion
- 14 Dec 2022
- Completion
- 14 Dec 2022
- Last update posted
- 31 Jan 2024
- Registered enrollment
- 29
- Registry id
- NCT04596319
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.